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Two-pore domain potassium channels (K2Ps) are characterised by their four transmembrane domain 
and two-pore topology. They carry background (or leak) potassium current in a variety of cell types. 
Despite a number of important roles there is currently a lack of pharmacological tools with which to 
further probe K2P function. We have developed a cell-based thallium flux assay, using baculovirus 
delivered TASK3 (TWIK-related acid-sensitive K
+
 channel 3, KCNK9, K2P9.1) with the aim of 
identifying novel, selective TASK3 activators. After screening a library of 1000 compounds, including 
drug-like and FDA approved molecules, we identified Terbinafine as an activator of TASK3. In a 
thallium flux assay a pEC50 of 6.2 (+/- 0.12) was observed. When Terbinafine was screened against 
TASK2, TREK2, THIK1, TWIK1 and TRESK no activation was observed in thallium flux assays. Several 
analogues of Terbinafine were also purchased and structure activity relationships examined. To 
confirm Terbinafine’s activation of TASK3 whole cell patch clamp electrophysiology was carried out 
and clear potentiation observed in both the wild type channel and the pathophysiological, Birk-Barel 
syndrome associated, G236R TASK3 mutant. No activity at TASK1 was observed in electrophysiology 
studies. In conclusion, we have identified the first selective activator of the two-pore domain 
potassium channel TASK3. 
 




Two-pore domain potassium channels (K2P), often referred to as ‘leak’ channels, primarily act to 




















15 channels, each sharing a distinct topology whereby channels comprise four transmembrane 
segments and two pore loops, forming functional dimers in the membrane. K2P channels are known 
to be regulated by a diverse set of modulators including physicochemical factors such as  
temperature, membrane stretch and pH, as well as signalling pathways including GPCRs and kinases 
and other interacting proteins e.g. 14-3-3 and Calcineurin. They have been implicated in an equally 
diverse set of pathophysiologies (summarized [1]).  
 
The TASK (TWIK-related acid-sensitive K+ channel) subfamily is comprised of 3 members TASK1, TASK3 
and TASK5. Thus far TASK5 mediated currents have not been demonstrated [2] but TASK1 and TASK3 
are functional channels which are highly sensitive to extracellular pH [3],[4]. TASK3 current is known 
to be reduced by extracellular acidification. TASK3 channels are found throughout the body with 
expression shown in the brain, heart, kidney, liver, colon, stomach, testis and skeletal muscle [4], [5].  
TASK3 KO mice show a number of cognitive impairments, including impaired working memory and 
altered circadian rhythms [6]. TASK3 has also been shown to function in the migration of cortical 
pyramidal neurons during development [7], whereby knockdown of TASK3 caused defective 
migration of late-born cortical excitatory neurons destined to become Layer II/III neurons. 
 
TASK3 has been implicated in a number of disorders including cancer [8], ischemia [9], low renin 
essential hypertension [10], idiopathic hyperalderosteronism [11] and epilepsy [12]. Of particular 
note is the observation mutations in TASK3 lead to Birk-Barel syndrome, a mental retardation 
syndrome characterized by intellectual disability, hypotonia, hyperactivity, and unusual facial 
features [12]. Birk-Barel syndrome  is also referred to as KCNK9 imprinting syndrome as TASK3 is the 
only K2P to be genetically imprinted – i.e. only the maternal copy of the gene is expressed [13]. The 
mutated channel, in which the glycine residue at position 236 is replaced by arginine (G236R), has a 




















showing the G236R TASK3 mutant channel function causes the previously described defective 
migration of neurons during development [7].    
 
Like many K2P channels further interrogation of TASK3 function has been limited by the paucity of 
selective pharmacological tools. A number of non-specific inhibitors have been described including 
zinc, ruthenium red, anandamide lidocaine, bupiviacine, alphaxolone and Gαq receptor agonists - 
notably M3 Muscarinic acetylcholine agonists [14].  A thallium-flux screen identified ML308 [15], a 
TASK3 inhibitor which shows 50-fold selectivity for TASK3 vs TASK1. Halogenated ether, alcohol, 
alkane anesthetics [16], TNFα [17] and flufenamic acid [18] have been shown to activate TASK3 but 
there remains an absence of specific TASK3 activators.  
 
The current study describes the development of a novel thallium flux TASK3 assay and the 
subsequent identification of Terbinafine as a potent activator of TASK3.  Selectivity was assessed 
against a number of alternative K2P channels and where possible activity confirmed using whole cell 




Thallium Flux assays 
U-2 OS cells (ATCC, UK) were maintained in MEM (Sigma, USA) supplemented with 10% FBS (Gibco, 
USA). TASK3 BacMam solution (SB Drug Discovery, UK) was used to generate transiently expressing 
cells. Typically, U-2 OS cells from liquid Nitrogen were thawed and re-suspended in media. Cells 




















desired concentration (v/v) of TASK3 BacMam solution. Typically for TASK3 BacMam was used at 5% 
v/v. Cells were plated on black, 384 well clear bottomed TC treated plates (Corning, USA) at 5k cells 
per well and incubated overnight at 37ᵒC and 5% CO2. The following day channel activity was 
measured using a FLIPR TETRA and the FLIPR Potassium assay kit (both Molecular Devices, USA). 
Compounds were all prepared in 100% DMSO and added to HBSS with 20mM HEPES. Compounds 
were then pre-incubated with cells for 30 minutes prior to thallium addition (final concentration of 
Tl
+
 2mM). Pre-addition baselines were established for 14 seconds and channel activity was 




To assess selectivity, U-2 OS cells were transduced with different baculovirus solutions to generate 
cells expressing TREK2, TASK2, TWIK1, THIK1 or TRESK. Cells were treated as described for TASK3 
and transduced with 1% v/v (TASK2, TREK2), 0.05% v/v THIK1, 10% v/v (TWIK1) or 0.5% v/v (TRESK) 
BacMam solution prior to plating on black, clear bottomed TC treated plates (Corning) at 5k cells per 
well and incubated overnight at 37ᵒC and 5% CO2. For TWIK1 the I239A/ I294A mutated variant was 
used to facilitate membrane expression. TWIK1 cells were also incubated for 48 hours before 
experiments. All cells were analyzed using the thallium flux assay as previously described for TASK3. 
To confirm activation, where available, control ligands were prepared in 100% DMSO and added to 
























Whole cell patch clamp 
 
tsA201 cells were grown as described previously [19]. For electrophysiological experiments, the 
pcDNA3.1 vector was cloned with the gene of interest (hTASK-3 (K2P9.1), hTASK-1 (K2P3.1) and 
hTASK-3_G236R). These vectors and a similar vector containing GFP were incorporated into the 
tsA201 cells (0.5 µg per well) using the calcium phosphate method. The cells were incubated for 6 - 
12 hours at 37
o
C in 95% oxygen and 5% carbon dioxide. Cells were then washed using a phosphate 
buffered saline solution (PBS), and used for experiments after 24 hours. 
 
Currents were recorded using whole cell patch clamp at room temperature using an Axopatch 1D 
amplifier. Cells were placed in a recording chamber filled  with an external medium composed of 145 
mM NaCl, 2.5 mM KCl, 3 mM MgCl2, 1 mM CaCl2 and 10 mM HEPES (pH to 7.4, using NaOH). The 
internal medium used in the glass pipette comprised 150 mM KCl, 3 mM MgCl2, 5 mM (or 0.1 mM) 
EGTA and 10 mM HEPES (pH to 7.4, using KOH). Terbinafine was applied by bath perfusion.  
 
Currents were recorded and analyzed using pCLAMP 10.2 software and Microsoft Excel. The voltage 
protocol used for recording current through K2P channels was as previously described [19].  For 
analysis, we measured the current difference between the -80 mV and - 40 mV steps. Data were 
expressed as mean ± standard error of the mean (SEM) and  ‘n’ represents the number of cells used 


























Tebinafine Hydrocholoride, Naftifine Hydrocholride and Butenafine Hydrocholride were purchased 
from Sigma Aldrich (UK). Cis-Terbinafine, N-Desmethyl Terbinafine and compound 6, Table 1 (as HCl 
salt) were purchased from Toronto Research chemicals Inc (Canada). A-1899 was purchased from 
Bionet (Camelford, UK). PK-THPP was purchased from Tocris (UK). TASK3 inhibitors, compound 3 (3-




For thallium flux assays data are mean +/- standard deviation (n≥3 independent experiments) unless 
stated.  Compound response curves were iteratively fitted to a four parameter logistic model using 
Graphpad Prism v7.01 (Graphpad, USA). Activity was defined as the rate of fluorescence increase 
measured using 470-495nM excitation LEDs and 515-575nM emission filter over a pre designated 
time period. This time period varied for each channel and is described appropriately. Baselines were 
established for 14 seconds prior to thallium addition. All data was acquired using ScreenWorks 4.0 



























Thallium flux assay development and identification of Terbinafine as a novel TASK3 activator 
 
Generation of cell lines stably expressing ion channels can be challenging for a number of reasons 
including inherent toxicity. Moreover, the ability to identify channel activators can be compromised 
by systems in which the target is over-expressed at high levels. To avoid these issues we utilized 
baculovirus (‘BacMam’) to deliver ion channels into mammalian cells. ‘BacMam’ confers a number of 
advantages, including safety and reduced time compared to generating stable cell lines but primarily 
it allowed the precise titratable expression of the gene of interest. With respect to K2Ps this enabled 
us to generate cell systems in which we were able to intricately and robustly select a level of TASK3 
expression, functionally optimized for the identification of channel activators. We have previously 
used this approach to successfully identify Cloxyquin as a novel activator of the K2P channel TRESK 
[21]. 
 
Initial experiments sought to demonstrate the ‘titratability’ of TASK3 expression using the thallium 
flux system as a measure of channel function. U-2 OS cells transduced with increasing levels of 
BacMam solution (Figure 1A), gave rise to increasing levels of channel function.  As described, K2P 
channel studies are limited by a lack of specific pharmacological tools, particularly regarding 
activators; therefore to ensure the thallium signal was representative of TASK3 activity a subset of 
known TASK3 inhibitors were used (Figure 1C). PK-THPP [22], A-1899 [23] and bis-amide scaffolds 
[20] although active for TASK1 have also been shown to inhibit TASK3. PK-THPP had a pIC50 of 8.20 




















those containing 3-CH3-phenyl or 4-pyridyl side groups [20]; these had pIC50s of 7.05 (+/- 0.37) and 
<5 respectively (Figure 1B).  
 
To identify novel activators of TASK3 we screened a library of approximately 1000 structurally 
diverse compounds. From this a small number of compounds were identified as increasing the rate 
of thallium flux above baseline, defined as >3 standard deviations of DMSO (no effect) controls. 
Putative hits were then re-screened against non-transduced cells to remove assay interferers (e.g. 
compounds which increase fluorescence independent of TASK3). This is another advantage of the 
BacMam system in that it allows screening against parental cells in the absence of the heterologous 
expressed ion channel. Terbinafine hydrochloride was identified as a robust activator of TASK3 and 
shown to have a pEC50 of 6.2 (+/- 0.12) whilst displaying no activity against wild type U-2 OS cells 
(Figure 1C). 
 
Electrophysiological analysis of Terbinafine confirms it is a subtype specific activator of TASK3 
 
To confirm Terbinafine’s activation of TASK3 whole cell electrophysiology experiments were 
conducted. Using tsA201 cells transiently transfected with wild type TASK3 1 µM Terbinafine was 
added and current measured using whole cell patch clamp recordings (Figure 2). Outward current 
was enhanced by 30% (+/- 3, n=5) and the zero current potential (reversal potential) hyperpolarised 
slightly from -86 mV (+/- 2) to -89 mV (+/- 2). The G236R variant of TASK3, linked to Birk-Barel 
syndrome has previously been described as having statistically reduced current density [18]. The 
effect of Terbinafine (1 µM) on G236A TASK3 was also analyzed.  A 76% (+/- 4, n=6) enhancement of 
current was observed and the zero current potential hyperpolarised from -77 mV (+/- 1) to -84 mV 




















that the mutated form is clearly activated to a high degree and indeed this may be as a functional 
consequence of lower starting activity.  
 
To assess the selectivity of Terbinafine between the TASK channel subtypes whole cell patch clamp 
recordings were also carried out on cells transiently transfected with TASK1. Experiments showed 
there was no enhancement of outward current at TASK1. After addition of 1 µM Terbinafine a 0% 
(+/- 4, n=5) change was observed. Importantly, changing to pH 8.4 markedly enhanced current in the 
same cells as those which do not respond to Terbinafine, confirming the channel was able to be 
potentiated by known physiological activators. These data confirm that Terbinafine is able to 
activate TASK3 and is subtype specific.  
 
Selectivity screening of Terbinafine and initial structure activity relationship analysis 
 
To assess the selectivity of Terbinafine we sought to analyze activity against a subset of alternative 
K2P channels, using a common thallium flux as a measure of channel activity. Initially, we measured 
activity at TREK2, TASK2, TWIK1, THIK1 and TRESK, representing at least one member of each of the 
K2P subfamilies.  Selectivity, in terms of activators, is complex to analyze at K2P channels as there is 
a lack of native ligands with which we can determine a maximal relative efficacy.  Additionally, 
differences in the level of efficacy with different ligands confound yet force comparison of agonist 
potency, activity relative to baseline and (where available) activity relative to a known activator.  It is 
also important to caveat that these activities are only relevant to the assay system used, in this case 
thallium flux, but might differ in an alternative assay format.  Two of the five channels initially tested 
have validated activators, 11-deoxy prostaglandin F-2α for TREK2 [24] and phorbol 12-myristate 13-




















activity 8.8 (+/- 0.33) fold over baseline, whereas maximal Terbinafine activity was only 1.77 (+/- 
0.22) over baseline (Figure 3). Additionally, based on an incomplete curve with a poorly defined 
maximum asymptote, Terbinafine’s pEC50 was <5 at TREK2. For TRESK maximal PMA activation was 
fold 1.39 (+/- 0.01) fold over baseline with a pEC50 of 8.22 (+/- 0.28) (Figure 3). Terbinafine showed 
no overt activation of TRESK with pEC50<5.  For TASK2 and THIK1 no activity could be observed 
(Figure 3). Interestingly Terbinafine showed inhibition at TWIK1 with a pIC50 of 5.69 (+/- 0.18) 
(Figure 3). This data suggests that Terbinafine is a highly selective activator with regards to other K2P 
channels.  
 
We also sought to define preliminary structural activity relationships (SAR) for Terbinafine activity at 
TASK3. As previously described Terbinafine (entry 1, Table 1) is an orally active antimycotic 
allylamine and a specific inhibitor of squalene epoxidase [26], which is used orally or topically to 
treat fungal infections. The commercially available analogues, entries 2 – 6 (Table 1), represent 
related allylamine antimycotics or, in the case of entry 6, an impurity isolated during the preparation 
of Terbinafine itself. These compounds were chosen to explore the effects of simple structural 
changes on TASK3 activation. These involved replacement of the triple bond with a phenyl group (in 
2 and 3), switching the stereochemistry of the double bond (in 4), demethylation of the basic centre 
(in 5) and methylation of the naphthalene ring (in 6).  Of the analogues tested only one, entry 6, 
retained the ability to activate TASK3 and this displayed near equipotent activity compared to 
Terbinafine itself. Of additional note is the observation that all of the Terbinafine analogues 
described in Table 1 showed near equipotent inhibition of TWIK1 (data not shown). This does not 

























Despite being associated with a number of human pathophysiologies, small molecule K2P channel 
modulators are not apparent and have yet to deliver therapeutics. Moreover, this lack of 
pharmacological tools has hindered understandings of the physiological role of K2P channels in 
native tissues.  In this study we aimed to identify novel activators of the TASK3 channel. We 
identified Terbinafine as a potent activator of TASK3 and in our assays it showed no significant 
activation of any other K2P channels tested. Activity of Terbinafine was confirmed using whole cell 
patch clamp electrophysiology and with potential relevance to the human developmental disorder, 
Birk-Barel syndrome, showed an increased level of activation of the G236R TASK3 variant compared 
to the wild type channel. 
 
As described Terbinafine, which is sold under the brand name Lamisil, is an antifungal treatment 
typically used for Dermatophytosis (ringworm/ tinea), pityriasis versicolor and Onychomycosis 
(fungal infection of the nail). As such it is generally thought of as being most effective on 
Dermatophyte fungi (Microsporum, Epidermophyton and Trichophyton). First approved in 1991 in 
Europe, it is on the World Health Organization's List of Essential Medicines. Although it’s primary 
mode of action is via inhibition of squalene epoxidase and thus synthesis of ergosterol [26], it is 
interesting to speculate as to whether activity at fungal K2P channels may play a role in Terbinafine’s 
antifungal activity. Yeast express a variant of the K2P channel, TOK1 and like human K2P channels 
this channel has also been shown to be activated by volatile anaesthetics [27], suggesting some 
shared pharmacology with human K2P channels. The activity of Terbinafine at TOK1 is not known 
but it represents a potentially interesting antifungal target given evidence has suggested TOK1 plays 





















The usefulness of Terbinafine in treating Birk-Barel is likely precluded by its unfavorable side-effect 
profile, particularly liver toxicity. It is also unlikely to cross the blood brain barrier (BBB) [29]. 
However, TASK3 activators have been shown to be efficacious in humans with this disorder. 
Mefanamic acid (MFA) has been reported as improving development and responsiveness [30]. The 
close analogue flufenamic acid (FFA) shows comparable activity to Terbinafine in whole cell patch 
clamp electrophysiology experiments at TASK3 and the G236R variant [18], albeit at much higher 
concentrations than used here for Terbinafine – 100 µM compared to 1 µM. Looking forward, it may 
be possible to develop Terbinafine analogues which do penetrate the BBB and with reduced side 
effect limitations.  
 
In conclusion, we have identified Terbinafine as a novel activator of the K2P channel TASK3 and it is 
hoped this activator will allow further studies into the physiological role of TASK3. We also describe 
a novel assay for identifying TASK3 activators and work is on-going to develop novel chemotypes 
which may be of therapeutic benefit in conditions where TASK3 activation is a requirement. It is 
hoped that the identification of a specific TASK3 activator may allow further interrogation of a target 
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 Figure / Table Legends  
 
 
Table 1 – SAR summary of Terbinafine analogues and activity at TASK3. TASK3 pEC50 determined 
using thallium flux assay.  
 
Figure 1 – (A) Assay development shows titration of BacMam correlates with TASK3 activity. 
Increasing amounts of BacMam (v/v) cause an increase in the rate of thallium flux into cells 
indicative of channel (TASK3) activity. (B) Pharmacology of TASK3 inhibitors. Exemplar 
concentration-response curves for A-1899 (circles), 3-CH3 phenyl variant of bis-amide scaffold 
(squares), 4-pyridyl variant of bis-amide scaffold (triangles) and PK-THPP (diamonds). (C) Terbinafine 
is an activator of TASK3. Exemplar compound response curves shows activity of Terbinafine at non-
transduced U-2 OS cells (circles) or U-2 OS cells transduced with 5% (v/v) TASK3 (squares). All graphs 
show rate of fluorescence increase between 14-24 seconds. Baseline established for 14 seconds 
before addition of 2mM Tl
+
. Error bars show standard deviation. 
 
Figure 2 - (A) Enhancement of TASK3, TASK3_G236R and TASK1 channels by terbinafine (1 µM). Time 
course of enhancement by terbinafine for TASK3 (B), TASK3_G236R (D) and TASK1 (F) channels. 
Effect of terbinafine on current voltage relationship for TASK3 (C), TASK3_G236R (E) and TASK1 
channels (G). The effect of alkaline pH (8.4) on TASK1 channels is also shown (F, G).   
 
Figure 3 – Activity of Terbinafine at selected K2P channels in thallium flux assays. (A) Terbinafine 
activity at TREK2. Compound response curves show activity of terbinafine compared to the known 




















response curves show activity of Terbinafine compared to the known TRESK activator Phorbol 12-
myristate 13-acetate (PMA). (C) Terbinafine activity at TASK2, THIK1 and TWIK1. For these channels 
no suitable activators were available. All graphs show rate of fluorescence increase between 
timepoints described on y axis. Baseline established for 14 seconds before addition of 2mM Tl
+
. Error 





























































































































































• Two-pore domain potassium channels (K2Ps) carry background (or leak) potassium current 
• Lack of specific, pharmacological tools for K2Ps 
• Developed a cell-based assay to identify activators of TASK3 
• Terbinafine is a selective activator of TASK3 
